Wells Fargo Maintains Equal-Weight on Oscar Health, Raises Price Target to $27
Wells Fargo analyst Stephen Baxter maintains Oscar Health (NYSE:OSCR) with a Equal-Weight and raises the price target from $20 to $27.
Stocks · News reference
Oscar Health Affirms FY2026 Sales Guidance of $18.700B-$19.000B vs $18.623B Est
Oscar Health (NYSE:OSCR) affirms FY2026 sales outlook from $18.700 billion-$19.000 billion to $18.700 billion-$19.000 billion vs $18.623 billion estimate.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
UBS Maintains Neutral on Oscar Health, Raises Price Target to $26
UBS analyst Jonathan Yong maintains Oscar Health (NYSE:OSCR) with a Neutral and raises the price target from $20 to $26.
Barclays Maintains Overweight on Oscar Health, Raises Price Target to $39
Oscar Health Raises Outlook But Warns CMS Membership Churn Will Pick Up
Oscar Health (OSCR) beat Q2 earnings with $4.88B revenue, but shares fell on expected ACA membership churn in H2. Read more.